**Melanoma**

**Observational**
- IRB#17104
- DecisionDx-Melanoma 31-Gene Expression Profile Clinical Impact Study

**Uveal Melanoma**
- IRB#16162
- A Phase I, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are Planned to Undergo Enucleation

**Adjuvant Therapies**
- IRB#11848
  - Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
- IRB#15661
  - A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
- IRB#16883
  - A Phase III, Randomized Study of Nivolumab with Ipilimumab vs. Ipilimumab or Nivolumab Monotherapy Post-resection

**Stages 2B, 2C, or 3**
- IRB#11848
- IRB#15661
- IRB#16883

**Stages 3 or 4, resectable**
- IRB#16198
  - A Phase I Dose Escalation Trial of Tumor Injections of TTI-621 in Subjects with Relapsed and Resistant Solid Tumors and Mycosis Fungoides

**Mutation Specific**
- IRB#17480
  - A randomized, double-blind, placebo-controlled, phase III study comparing the combination of PDR001, dabrafenib and trametinib versus placebo, dabrafenib and trametinib in previously untreated patients with unresectable or metastatic BRAF V600 mutant melanoma

**Non-Mutation Specific**
- IRA#15661

**Stages 3 or 4, unresectable**
- IRB#15661

Please refer to Phase I studies for more clinical trial opportunities.

**Adjuvant Therapies**

**Mutation Specific**
- BRAF V600 Mutation

**Stage Specific**
- Stages 2B, 2C, or 3
- Stages 3 or 4, resectable
- Stages 3 or 4, unresectable

**Gene Expression Profile Clinical Impact Study**

**Key**
- Open for Enrollment
- In Development
- Enrollment on Hold

*http://www.ohsu.edu/research/rda/so/knight.php*